Shareholders Will Be Pleased With The Quality of Infinium Pharmachem's (NSE:INFINIUM) Earnings
Infinium Pharmachem Limited (NSE:INFINIUM) just reported healthy earnings but the stock price didn't move much. Our analysis suggests that investors might be missing some promising details.
A Closer Look At Infinium Pharmachem's Earnings
As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. The ratio shows us how much a company's profit exceeds its FCF.
Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".
Over the twelve months to September 2026, Infinium Pharmachem recorded an accrual ratio of -0.10. That indicates that its free cash flow was a fair bit more than its statutory profit. To wit, it produced free cash flow of ₹286m during the period, dwarfing its reported profit of ₹154.8m. Given that Infinium Pharmachem had negative free cash flow in the prior corresponding period, the trailing twelve month resul of ₹286m would seem to be a step in the right direction.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Infinium Pharmachem.
Our Take On Infinium Pharmachem's Profit Performance
As we discussed above, Infinium Pharmachem has perfectly satisfactory free cash flow relative to profit. Based on this observation, we consider it likely that Infinium Pharmachem's statutory profit actually understates its earnings potential! And the EPS is up 17% annually, over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. At Simply Wall St, we found 2 warning signs for Infinium Pharmachem and we think they deserve your attention.
Today we've zoomed in on a single data point to better understand the nature of Infinium Pharmachem's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.